MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation

Jian Ma,Lei Li,Bohan Ma,Tianjie Liu,Zixi Wang,Qi Ye,Yunhua Peng,Bin Wang,Yule Chen,Shan Xu,Ke Wang,Fabin Dang,Xinyang Wang,Zixuan Zeng,Yanlin Jian,Zhihua Ren,Yizeng Fan,Xudong Li,Jing Liu,Yang Gao,Wenyi Wei,Lei Li

DOI: https://doi.org/10.1038/s41467-024-45796-w

IF: 16.6

2024-02-29

Nature Communications

Abstract:Abstract CDK4/6 inhibitors (CDK4/6i) show anticancer activity in certain human malignancies, such as breast cancer. However, their application to other tumor types and intrinsic resistance mechanisms are still unclear. Here, we demonstrate that MYC amplification confers resistance to CDK4/6i in bladder, prostate and breast cancer cells. Mechanistically, MYC binds to the promoter of the E3 ubiquitin ligase KLHL42 and enhances its transcription, leading to RB1 deficiency by inducing both phosphorylated and total pRB1 ubiquitination and degradation. We identify a compound that degrades MYC, A80.2HCl, which induces MYC degradation at nanomolar concentrations, restores pRB1 protein levels and re-establish sensitivity of MYC high-expressing cancer cells to CDK4/6i. The combination of CDK4/6i and A80.2HCl result in marked regression in tumor growth in vivo. Altogether, these results reveal the molecular mechanisms underlying MYC-induced resistance to CDK4/6i and suggest the utilization of the MYC degrading molecule A80.2HCl to potentiate the therapeutic efficacy of CDK4/6i.

multidisciplinary sciences

What problem does this paper attempt to address?

This paper aims to explore and solve the following problems:

**How does MYC lead to resistance to CDK4/6 inhibitors?**

Specifically, the study found that over - expression of MYC promotes the ubiquitination and degradation of pRB1, resulting in cell resistance to CDK4/6 inhibitors (such as palbociclib). The main mechanisms are as follows:

1. **The relationship between MYC and KLHL42**:
- MYC can bind to the promoter region of the E3 ubiquitin - ligase KLHL42 gene and enhance its transcription.
- After over - expressing MYC, the expression of KLHL42 increases, which in turn leads to the ubiquitination and degradation of pRB1, reducing the level of pRB1 protein.

2. **The degradation mechanism of pRB1**:
- The study found that over - expression of MYC leads to a decrease in the protein level of pRB1, and this process is achieved through the proteasome pathway.
- By knocking down MYC or KLHL42, the protein level of pRB1 can be restored and its half - life can be prolonged.

3. **The role of the MYC - degrading molecule A80.2HCl**:
- The researchers screened and identified a small - molecule compound named A80.2HCl, which can effectively degrade MYC protein at nanomolar concentrations.
- A80.2HCl restores the protein level of pRB1 and re - establishes cell sensitivity to CDK4/6 inhibitors by binding to GSPT1 and MYC and recruiting CRBN for degradation.

4. **The effect of combination therapy**:
- The experimental results show that the combined use of CDK4/6 inhibitors and A80.2HCl can significantly inhibit tumor growth, showing a synergistic effect.

In summary, this paper reveals the molecular mechanism by which MYC leads to CDK4/6 inhibitor resistance by promoting pRB1 degradation, and proposes a potential treatment strategy, that is, using the MYC - degrading molecule A80.2HCl to improve the efficacy of CDK4/6 inhibitors.